If you're looking to add a few ASX 200 blue chip shares to your portfolio in August, then the three listed below could be worth considering.
I believe these blue chips could generate solid returns for investors over the next few years. Here's why I would buy them:
CSL Limited (ASX: CSL)
The first blue chip I would buy is this global biotherapeutics company. I think it has the potential to provide investors with strong returns over the next decade, especially after recent weakness in the CSL share price. This has been caused by concerns over plasma collections during the pandemic and the impact this could have on its FY 2021 results. However, I'm optimistic this will be offset by other sides of the business, such as flu vaccine sales. In light of this, I think investors should focus on the long term, which remains very positive. This is due to its leading therapies and lucrative research and development pipeline.
Goodman Group (ASX: GMG)
Another blue chip ASX 200 share to consider buying is Goodman Group. It is an integrated commercial and industrial property group with a high quality portfolio of assets. It remains my favourite option in the property sector due to its exposure to industries benefiting from structural tailwinds such as ecommerce. These assets are likely to be in demand for many years to come, which I believe leaves it well-positioned for solid long term growth.
REA Group Limited (ASX: REA)
A final option to consider buying is this property listings company. Times have been hard to REA Group over the last few years, but thanks to its high quality business model, it has still managed to deliver strong profits. And although the tough trading conditions are likely to remain for at least the next couple of quarters, I wouldn't let that put you off investing. I expect REA Group's growth to accelerate materially once things return to normal. Especially given its leadership position, growing global operations, new revenue streams, potential price increases, and cost cutting.
